Johnson & Johnson (NYSE:JNJ) Shares Down 1.6% – Here’s Why

Shares of Johnson & Johnson (NYSE:JNJ) fell 1.6% during trading on Tuesday. The stock traded as low as $265.28 and last traded at $266.1040. Approximately 6,454,019 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 7,943,411 shares. The stock had previously closed at $270.56.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the TCT 2026 meeting, real-world analyses of 1,379 patients treated with Impella during high-risk coronary procedures showed lower mortality than in a prior study. A separate report cited a 94% success rate. The findings could support adoption of J&J’s heart-pump business, though further evidence is expected from the ongoing PROTECT IV trial. Article: What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Positive Sentiment: ETFs purchased $35.1 million of JNJ shares on Oct. 29, a modest indication of institutional demand. Article: ETFs Are Buying Johnson & Johnson
• Neutral Sentiment: JNJ has drawn increased investor attention, but the Zacks article provides no specific new forecast or company development to explain the interest. Article: Is Trending Stock Johnson & Johnson a Buy Now?
• Negative Sentiment: One analysis questions whether the shares are fully valued after a strong recent and longer-term advance. That debate could temper investor enthusiasm even as the Impella data adds to the company’s growth story. Article: Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Citigroup raised their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday, October 5th. Finally, UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Stock Down 1.6%

The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm has a 50-day moving average of $265.74 and a 200 day moving average of $247.22. The stock has a market capitalization of $640.59 billion, a price-to-earnings ratio of 40.32, a PEG ratio of 2.68 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the firm earned $2.80 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last three months. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several hedge funds have recently modified their holdings of the stock. Pictet Asset Management Holding SA lifted its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,864,710 shares of the company’s stock valued at $493,666,000 after acquiring an additional 11,452 shares in the last quarter. Verus Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 6.0% in the 3rd quarter. Verus Capital Partners LLC now owns 8,026 shares of the company’s stock valued at $2,125,000 after acquiring an additional 456 shares in the last quarter. AlphaCentric Advisors LLC grew its position in Johnson & Johnson by 11.4% in the third quarter. AlphaCentric Advisors LLC now owns 1,549 shares of the company’s stock worth $410,000 after acquiring an additional 158 shares in the last quarter. Tennessee Valley Asset Management Partners lifted its holdings in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Tennessee Valley Asset Management Partners now owns 3,211 shares of the company’s stock worth $850,000 after acquiring an additional 48 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in Johnson & Johnson by 2.6% during the 3rd quarter. Parallel Advisors LLC now owns 85,192 shares of the company’s stock worth $22,554,000 after acquiring an additional 2,157 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.